Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis

European Journal of Pharmacology

Volumn 535, Issue 1-3, 2006, Pages 34-42

  Tavridou, Anna ^a,b   Kaklamanis, Loukas ^c   Megaritis, George ^a   Kourounakis, Angeliki P ^a,d   Papalois, Apostolos ^a   Roukounas, Dimitris ^a   Rekka, Eleni A ^e   Kourounakis, Panos N ^e   Charalambous, Avgui ^a   Manolopoulos, Vangelis G ^b  

^a ELPEN Pharmaceutical Co Inc   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c ONASSIS CARDIAC SURGERY CENTER   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

2 Biphenylmorpholine compounds; Apolipoprotein B; Cholesterol; Low density lipoprotein receptor; Squalene synthase inhibitor; Triglyceride

Indexed keywords

2 (4 BIPHENYL) 2 (3 NITROOXYPROPOXY) 4 METHYLMORPHOLINE; 2 (4 BIPHENYL) 4 METHYLOCTAHYDRO 1,4 BENZOXAZIN 2 OL; APOLIPOPROTEIN B; CHOLESTEROL; EP 2300; EP 2302; EP 2306; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; MORPHOLINE DERIVATIVE; SIMVASTATIN; SQUALENE SYNTHASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIPOGENESIS; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TRANSPORT;

ANIMALS; APOLIPOPROTEINS B; BIOLOGICAL TRANSPORT; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MICROSCOPY, FLUORESCENCE; MICROSOMES, LIVER; MORPHOLINES; RABBITS; RECEPTORS, LDL; SIMVASTATIN; TRIGLYCERIDES;

EID: 33645395710     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.02.006     Document Type: Article

References (45)

1. Y. Amano, T. Nishimoto, R. Tozawa, E. Ishikawa, Y. Imura, and Y. Sugiyama Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia Eur. J. Pharmacol. 466 2003 155 161
2. D. Amin, S.A. Cornell, S.K. Gustafson, S.J. Needle, J.W. Ullrich, G.E. Bilder, and M.H. Perrone Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis J. Lipid Res. 33 1992 1657 1663
3. D. Amin, R.Z. Rutledge, S.N. Needle, H.F. Galczenski, K. Neuenschwander, A.C. Scotese, M.P. Maguire, R.C. Bush, D.J. Hele, G.E. Bilder, and M.H. Perrone RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase J. Pharmacol. Exp. Ther. 281 1997 746 752
4. A. Baxter, B.J. Fitzgerald, J.L. Hutson, A.D. McCarthy, J.M. Motteram, B.C. Ross, M. Sapra, M.A. Snowden, N.S. Watson, R.J. Williams, and C. Wright Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo J. Biol. Chem. 267 1992 11705 11708
5. J.D. Bergstrom, M.M. Kurtz, D.J. Rew, A.M. Amend, J.D. Karkas, R.G. Bostedor, V.S. Bansal, C. Dufresne, F.L. VanMiddlesworth, O.D. Hensens, J.M. Liesch, D.L. Zink, K.E. Wilson, J. Onishi, J.A. Milligan, G. Bills, L. Kaplan, M. Nallin Omstead, R.G. Jenkins, L. Huang, M.S. Meinz, L. Quinn, R.W. Burg, Y.L. Kong, S. Mochales, M. Mojena, I. Martin, F. Pelaez, M.T. Diez, and A.W. Alberts Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase Proc. Natl. Acad. Sci. U. S. A. 90 1993 80 84
6. J.D. Bergstrom, R.G. Bostedor, D.J. Rew, W.M. Geissler, S.D. Wright, and Y.S. Chao Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim Biophys. Acta 1389 1998 213 221
7. S.A. Biller, C. Forster, E.M. Gordon, T. Harrity, L.C. Rich, J. Marretta, and C.P. Ciosek Jr. Isoprenyl phosphinylformates: new inhibitors of squalene synthetase J. Med. Chem. 34 1991 1912 1914
8. G.R. Brown, D.S. Clarke, A.J. Foubister, S. Freeman, P.J. Harrison, M.C. Johnson, K.B. Mallion, J. McCormick, F. McTaggart, A.C. Reid, G.J. Smith, and M.J. Taylor Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors J. Med. Chem. 39 1996 2971 2979
9. L. Chan Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins J. Biol. Chem. 267 1992 25621 25624
10. M.C. Chrysselis, E.A. Rekka, and P.N. Kourounakis Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity J. Med. Chem. 43 2000 609 612
11. M.C. Chrysselis, E.A. Rekka, I.C. Siskou, and P.N. Kourounakis Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents J. Med. Chem. 45 2002 5406 5409
12. C.P. Ciosek Jr., D.R. Magnin, T.W. Harrity, J.V. Logan, J.K. Dickson Jr., E.M. Gordon, K.A. Hamilton, K.G. Jolibois, L.K. Kunselman, R.M. Lawrence, K.A. Mookhtiar, L.C. Rich, D.A. Slusarchyk, R.B. Sulsky, and S.A. Biller Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo J. Biol. Chem. 268 1993 24832 24837
13. J.K. Dickson Jr., S.A. Biller, D.R. Magnin, E.W. Petrillo Jr., J.W. Hillyer, D.C. Hsieh, S.J. Lan, J.K. Rinehart, R.E. Gregg, T.W. Harrity, K.G. Jolibois, S.S. Kalinowski, L.K. Kunselman, K.A. Mookhtiar, and C.P. Ciosek Jr. Orally active squalene synthase inhibitors: bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety J. Med. Chem. 39 1996 661 664
14. E.A. Fisher, and H.N. Ginsberg Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins J. Biol. Chem. 277 2002 17377 17380
15. T. Funatsu, K. Suzuki, M. Goto, Y. Arai, H. Kakuta, H. Tanaka, S. Yasuda, M. Ida, S. Nishijima, and K. Miyata Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apoB-100 and triglyceride secretion from HepG2 cells Atherosclerosis 157 2001 107 115
16. H.N. Ginsberg Synthesis and secretion of apolipoprotein B from cultured liver cells Curr. Opin. Lipidol. 6 1995 275 280
17. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425 430
18. C.D. Goodwin, and S. Margolis Improved methods for the study of hepatic HMG CoA reductase: one-step isolation of mevalonolactone and rapid preparation of endoplasmic reticulum J. Lipid Res. 17 1976 297 303
19. T. Grand-Perret, A. Bouillot, A. Perrot, S. Commans, M. Walker, and M. Issandou SCAP ligands are potent new lipid-lowering drugs Nat. Med. 7 2001 1332 1338
20. Group 4S Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
21. H. Hiyoshi, M. Yanagimachi, M. Ito, I. Ohtsuka, I. Yoshida, T. Saeki, and H. Tanaka Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors J. Lipid Res. 41 2000 1136 1144
22. H. Hiyoshi, M. Yanagimachi, M. Ito, T. Saeki, I. Yoshida, T. Okada, H. Ikuta, D. Shinmyo, K. Tanaka, N. Kurusu, and H. Tanaka Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism Eur. J. Pharmacol. 431 2001 345 352
23. H. Hiyoshi, M. Yanagimachi, M. Ito, N. Yasuda, T. Okada, H. Ikuta, D. Shinmyo, K. Tanaka, N. Kurusu, I. Yoshida, S. Abe, T. Saeki, and H. Tanaka Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes J. Lipid Res. 44 2003 128 135
24. J. Jeppesen, H.O. Hein, P. Suadicani, and F. Gyntelberg Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study Circulation 97 1998 1029 1036
25. D.J. Kornbrust, J.S. MacDonald, C.P. Peter, D.M. Duchai, R.J. Stubbs, J.I. Germershausen, and A.W. Alberts Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits J. Pharmacol. Exp. Ther. 248 1989 498 505
26. R.C. Laughlin, and T.F. Carey Cataracts in patients treated with triparanol J. Am. Med. Assoc. 181 1962 339 340
27. D.R. Magnin, S.A. Biller, Y. Chen, J.K. Dickson Jr., O.M. Fryszman, R.M. Lawrence, J.V. Logan, E.S. Sieber-McMaster, R.B. Sulsky, S.C. Traeger, D.C. Hsieh, S.J. Lan, J.K. Rinehart, T.W. Harrity, K.G. Jolibois, L.K. Kunselman, L.C. Rich, D.A. Slusarchyk, and C.P. Ciosek Jr. alpha-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase J. Med. Chem. 39 1996 657 660
28. B.A. Masters, M.J. Palmoski, O.P. Flint, R.E. Gregg, D. Wang-Iverson, and S.K. Durham In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes Toxicol. Appl. Pharmacol. 131 1995 163 174
29. F. McTaggart, G.R. Brown, R.G. Davidson, S. Freeman, G.A. Holdgate, K.B. Mallion, D.J. Mirrlees, G.J. Smith, and W.H. Ward Inhibition of squalene synthase of rat liver by novel 3′ substituted quinuclidines. Biochem. Pharmacol. 51 1996 1477 1487
30. V.C. Menys, and P.N. Durrington Squalene synthase inhibitors Br. J. Pharmacol. 139 2003 881 882
31. C.S. Moran, J.H. Campbell, and G.R. Campbell Human leukemia inhibitory factor upregulates LDL receptors on liver cells and decreases serum cholesterol in the cholesterol-fed rabbit Arterioscler. Thromb. Vasc. Biol. 17 1997 1267 1273
32. S. Murakami, I. Nitanai, S. Uchida, Y. Kondo-Ohta, Y. Asami, K. Kondo, M. Sato, A. Kawashima, H. Hara, K. Tomisawa, H.B. Mei, and C.Z. Xiang Up-regulation of low density lipoprotein receptor by a novel isobenzofranone derivative, MD-700 Atherosclerosis 146 1999 281 290
33. T. Nishimoto, Y. Amano, R. Tozawa, E. Ishikawa, Y. Imura, H. Yukimasa, and Y. Sugiyama Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro Br. J. Pharmacol. 139 2003 911 918
34. C.R. Pullinger, J.D. North, B.B. Teng, V.A. Rifici, A.E. Ronhild de Brito, and J. Scott The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life J. Lipid Res. 30 1989 1065 1077
35. H. Scharnagl, R. Schinker, H. Gierens, M. Nauck, H. Wieland, and W. Marz Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells Biochem. Pharmacol. 62 2001 1545 1555
36. A. Sharma, P.H. Slugg, J.L. Hammett, and W.J. Jusko Estimation of oral bioavailability of a long half-life drug in healthy subjects Pharm. Res. 15 1998 1782 1786
37. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, J.H. McKillop, and C.J. Packard Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N. Engl. J. Med. 333 1995 1301 1307
38. A. Tavridou, and V.G. Manolopoulos Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo Eur. J. Pharmacol. 505 2004 213 221
39. T. Ugawa, H. Kakuta, H. Moritani, K. Matsuda, T. Ishihara, M. Yamaguchi, S. Naganuma, Y. Iizumi, and H. Shikama YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species Br. J. Pharmacol. 131 2000 63 70
40. T. Ugawa, H. Kakuta, H. Moritani, and O. Inagaki Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters Br. J. Pharmacol. 137 2002 561 569
41. T. Ugawa, H. Kakuta, H. Moritani, O. Inagaki, and H. Shikama YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents Br. J. Pharmacol. 139 2003 140 146
42. W.H. Ward, G.A. Holdgate, S. Freeman, F. McTaggart, P.A. Girdwood, R.G. Davidson, K.B. Mallion, G.R. Brown, and M.A. Eakin Inhibition of squalene synthase in vitro by 3-(biphenyl-4-yl)-quinuclidine Biochem. Pharmacol. 51 1996 1489 1501
43. G.F. Watts, R. Naoumova, M.H. Cummings, A.M. Umpleby, B.M. Slavin, P.H. Sonksen, and G.R. Thompson Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects Metabolism 44 1995 1052 1057
44. Z. Yao, and R.S. McLeod Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins Biochim. Biophys. Acta 1212 1994 152 166
45. Z. Yao, K. Tran, and R.S. McLeod Intracellular degradation of newly synthesized apolipoprotein B J. Lipid Res. 38 1997 1937 1953